NCT07030127View on ClinicalTrials.gov

A Study of LY3985863 in Healthy Participants

PHASE1RecruitingINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

August 11, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Healthy

Interventions

DRUG

LY3985863

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (1)

100191

RECRUITING

Peking University Third Hospital, Beijing

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY